An observational study in Idiopathic Pulmonary Fibrosis, sponsored by University of Pittsburgh. Completed at 5 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of Pittsburgh · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 25th largest by enrollment of the 45 observational ones that give a count, is one of 11 that started in 2015, is one of 46 observational ones, and was the 89th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Oorja Bio, Inc. · Sites in United States
Ages 40+
University of California, San Francisco · Sites in United States
Ages 18+
Trevi Therapeutics · Sites in United States
Ages 40+
Joseph C. Wu · Sites in United States
Ages 40+
Chiesi Farmaceutici S.p.A. · Sites in United States, North Macedonia, Korea, Republic of and 1 more country
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 89 · Phase 3 39 · Phase 4 6
First in 1999; this study’s year is marked. 11 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 152 across 165 observational studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 61 across the 188 interventional studies, 320 across the 45 observational. Of the 170 that completed or were terminated, 86 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 236 have an industry lead sponsor. The 10 most frequent:
University of Pittsburgh is the lead sponsor of 1,422 studies on the registry; 170 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
University of Pittsburgh has 5 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
15 of the studies in Idiopathic Pulmonary Fibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT07868419Phase 3Trevi TherapeuticsIdiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets | 2027-08 |
| NCT06736990Calluna Pharma ASA Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | 2026-11 |
| NCT06853145University of VirginiaHyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis | 2026-12 |
| NCT03478553University of Colorado, DenverThe Genetics of Pulmonary Fibrosis | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the PaTH Network IPF Clinician-Patient Partnership Cohort is to use clinical data from electronic health records (EHR) and patient reported outcomes (PRO) to answer questions of clinical importance to patients with Idiopathic Pulmonary Fibrosis, providers, and other stakeholders.
The primary objective is to create the PaTH Network IPF Clinician-Patient Partnership Cohort, which will allow the conduct of patient-centered observational studies on IPF across the multiple institutions (Hershey Penn State, University of Pittsburgh, Temple University) of the PaTH network. Creating the IPF Clinician-Patient Partnership Cohort will involve:
The secondary objectives are to use the PaTH Network IPF Clinician-Patient Partnership Cohort to answer patient-centered research questions including:
The target study population is adults with IPF who receive health care at one of the PaTH Network institutions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Create PaTH Network IPF Clinician-Patient Partnership Cohort
Create the PaTH Network IPF Clinician-Patient Partnership Cohort, which will allow the conduct of patient-centered observational studies on IPF across the multiple institutions (Hershey Penn State, University of Pittsburgh, Temple University) of the PaTH network.
Time frame: 18 months
Ran from Jun 2015 to primary completion in Oct 2015, 4 months.
Of 74 non-industry observational studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 102. This study's 4 months is below that.
Counting every sponsor, half of 88 studies reached it within 51 months; a quarter within 29 and three quarters within 96.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Mar 2015 → Jun 2015, primary completion Jul 2030 → Oct 2015 and completion Jul 2030 → Oct 2017.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idiopathic Pulmonary Fibrosis →